MCID: ORL005
MIFTS: 48

Oral Candidiasis malady

Categories: Infectious diseases, Oral diseases

Aliases & Classifications for Oral Candidiasis

Aliases & Descriptions for Oral Candidiasis:

Name: Oral Candidiasis 12 52 14 69
Thrush 12 3 14
Candidiasis of Mouth 12
Candidiasis, Oral 42
Oral Moniliasis 12
Equine Thrush 69
Thrush, Oral 12
Candidiasis 69

Classifications:



External Ids:

Disease Ontology 12 DOID:14262
ICD10 33 B37.0 B37.9
ICD9CM 35 112.0
MeSH 42 D002180
NCIt 47 C28137
UMLS 69 C0006849

Summaries for Oral Candidiasis

CDC : 3 Candidiasis of the mouth and throat, also known as “thrush" or oropharyngeal candidiasis, is a fungal infection that occurs when there is overgrowth of a yeast called Candida. Candida yeasts normally live on the skin or mucous membranes in small amounts. However, if the environment inside the mouth or throat becomes imbalanced, the yeasts can multiply and cause symptoms. Candida overgrowth can also develop in the esophagus, and this is called Candida esophagitis, or esophageal candidiasis.

MalaCards based summary : Oral Candidiasis, also known as thrush, is related to immunodeficiency 32b, monocyte and dendritic cell deficiency, autosomal recessive and median rhomboid glossitis, and has symptoms including oral manifestations An important gene associated with Oral Candidiasis is DEFB4A (Defensin Beta 4A), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, colon and tongue, and related phenotype is Increased shRNA abundance (Z-score > 2).

Disease Ontology : 12 A candidiasis that involves fungal infection of the mucous membrane of the mouth by Candida species, which is characterized by thick white or cream-colored deposits on inflamed mucosal membranes.

Wikipedia : 71 Oral candidiasis, also known as oral thrush among other names, is candidiasis that occurs in the mouth.... more...

Related Diseases for Oral Candidiasis

Diseases related to Oral Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
id Related Disease Score Top Affiliating Genes
1 immunodeficiency 32b, monocyte and dendritic cell deficiency, autosomal recessive 11.0
2 median rhomboid glossitis 10.9
3 candidiasis 10.8
4 nodular basal cell carcinoma 10.3 DEFA1 DEFB4A
5 coronary arterial fistulas 10.2 CXCL8 LTF
6 psychotic disorder 10.2 CXCL8 LTF
7 retinal vascular disease 10.2 CXCL8 LTF
8 scleroderma, familial progressive 10.2 CXCL8 LTF
9 handl syndrome 10.2 CXCL8 LTF
10 microglandular adenosis of breast 10.2 CXCL8 IL1A
11 bowman's membrane folds or rupture 10.2 DEFB1 DEFB4A
12 neonatal antiphospholipid syndrome 10.2 DEFB1 DEFB4A
13 spastic hemiplegia 10.2 DEFB4A IL1A
14 renovascular hypertension 10.1 CXCL8 IL1A
15 carcinoid tumor childhood 10.1 HTN3 SKAP2
16 denture stomatitis 10.1 B2M SKAP2
17 stomach carcinoma in situ 10.1 CXCL8 DEFB4A IL1A
18 inappropriate adh syndrome 10.1 CXCL8 DEFB4A IL1A
19 gonadal disease 10.1 DEFB1 DEFB4A
20 tibial nerve palsy 10.1 B2M SKAP2
21 leukoplakia 10.1
22 chronic gonorrhea of cervix 10.1 DEFB4A HTN3 SKAP2
23 mikulicz disease 10.1 IL1A LTF
24 vascular dementia 10.1 DEFB1 DEFB4A IL1A
25 bacterial gastritis 10.0 CXCL8 DEFB1 DEFB4A
26 polyneuropathy due to drug 10.0 CD4 IL1A
27 ciliary discoordination, due to random ciliary orientation 10.0 CD4 IL1A
28 total internal ophthalmoplegia 10.0 CD4 CXCL8
29 nasopharyngitis 10.0 CXCL8 DEFB1 IL1A
30 autoimmune polyendocrine syndrome type 1 10.0 CD4 CXCL8
31 stenosis of lacrimal sac 10.0 CXCL8 DEFB4A IL1A LTF
32 hypoparathyroidism-retardation-dysmorphism syndrome 10.0 CD4 LTF
33 waldeyer's ring cancer 10.0 CD4 DEFB4A LTF
34 mucositis 10.0
35 carbuncle 10.0 CD4 CXCL8
36 oral hairy leukoplakia 10.0
37 perinatal necrotizing enterocolitis 9.9 CD4 LTF
38 46 xy gonadal dysgenesis 9.9 B2M CD4
39 bullous retinoschisis 9.9 CD4 CXCL8 DEFB4A
40 bacteriuria 9.9 B2M CD4
41 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 9.9 CD4 LTF
42 sarcomatoid transitional cell carcinoma 9.9 CD4 DEFA1 IL1A
43 glucose intolerance 9.9 B2M CXCL8
44 acute kidney failure 9.9 CXCL8 DEFB1 DEFB4A IL1A
45 histiocytosis 9.9 CXCL8 DEFB1 DEFB4A IL1A
46 intratubular embryonal carcinoma 9.9 CXCL8 DEFB1 DEFB4A IL1A
47 childhood malignant hemangiopericytoma 9.9 CD4 CXCL8 LTF
48 bone angioendothelial sarcoma 9.9 CD4 CXCL8 IL1A
49 acquired immunodeficiency syndrome 9.9
50 leukemia 9.8

Comorbidity relations with Oral Candidiasis via Phenotypic Disease Network (PDN): (show all 37)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alzheimer Disease Anxiety Disorder
Bronchitis Bronchopneumonia
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophageal Candidiasis
Esophagitis Familial Atrial Fibrillation
Glossitis Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Neutropenia Osteoporosis
Paralytic Ileus Peripheral Vascular Disease
Pharyngitis Pituitary Adenoma, Acth-Secreting
Pneumocystosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure
Rheumatoid Arthritis Schizophreniform Disorder
Status Asthmaticus Swallowing Disorders
Vulvovaginal Candidiasis

Graphical network of the top 20 diseases related to Oral Candidiasis:



Diseases related to Oral Candidiasis

Symptoms & Phenotypes for Oral Candidiasis

UMLS symptoms related to Oral Candidiasis:


oral manifestations

GenomeRNAi Phenotypes related to Oral Candidiasis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.36 DEFB4A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.36 CD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.36 DEFA1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.36 DEFA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.36 DEFA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.36 CD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.36 DEFA1 CD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.36 DEFA1 DEFB4A CD4

Drugs & Therapeutics for Oral Candidiasis

Drugs for Oral Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
3
Anidulafungin Approved, Investigational Phase 4,Phase 3 166663-25-8 166548
4
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2 137234-62-9 71616
5
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2 23593-75-1 2812
6
Terconazole Approved Phase 4,Early Phase 1 67915-31-5 441383
7
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2 1400-61-9 11953884
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 1 84625-61-6 55283
10
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
11
Mycophenolic acid Approved Phase 4 24280-93-1 446541
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13 Adrenergic Agents Phase 4,Phase 3,Phase 2
14 Adrenergic Agonists Phase 4,Phase 3,Phase 2
15 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 3,Phase 2
16 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
17 Anti-Allergic Agents Phase 4,Phase 3,Phase 2
18 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
20 Autonomic Agents Phase 4,Phase 3,Phase 2
21 Bronchodilator Agents Phase 4,Phase 3,Phase 2
22 Dermatologic Agents Phase 4,Phase 3,Phase 2
23
Fluticasone Phase 4,Phase 3,Phase 2 90566-53-3, 80474-14-2 62924 22833648
24 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 3
25 glucocorticoids Phase 4,Phase 3,Phase 2
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
31 Respiratory System Agents Phase 4,Phase 3,Phase 2
32
Salmeterol xinafoate Phase 4,Phase 3 94749-08-3 56801
33 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3
40 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Echinocandins Phase 4,Phase 3,Phase 2
42 Anti-Infective Agents, Local Phase 4,Phase 3
43 Ionophores Phase 4,Phase 3
44 Castor Oil Phase 4
45 Disinfectants Phase 4
46 Epinephryl borate Phase 4
47 Eusol Phase 4
48 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
49 Racepinephrine Phase 4
50
s 1 (combination) Phase 4

Interventional clinical trials:

(show top 50) (show all 113)
id Name Status NCT ID Phase
1 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4
2 Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week Unknown status NCT00537888 Phase 4
3 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4
4 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4
5 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4
6 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00548262 Phase 4
7 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4
8 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4
9 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4
10 Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients Completed NCT01495039 Phase 4
11 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4
12 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
13 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4
14 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4
15 Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Completed NCT00002446 Phase 3
16 A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed NCT00128323 Phase 3
17 Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Completed NCT00666185 Phase 3
18 Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis Completed NCT00665639 Phase 3
19 Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis Completed NCT02184351 Phase 3
20 Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic Completed NCT02818803 Phase 3
21 A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Completed NCT00001812 Phase 3
22 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed NCT01427738 Phase 3
23 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3
24 Effect of Probiotic Lozenge on Gingivitis and Periodontitis Completed NCT02203812 Phase 3
25 Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma Completed NCT02175771 Phase 3
26 Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy Completed NCT00152867 Phase 3
27 Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study Completed NCT01018186 Phase 3
28 Prophylactic Antibiotics in Measles Completed NCT00168532 Phase 3
29 Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy Completed NCT02181335 Phase 3
30 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Completed NCT00689338 Phase 3
31 A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems Completed NCT00002339 Phase 3
32 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3
33 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3
34 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed NCT00784368 Phase 3
35 A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. Completed NCT00163111 Phase 3
36 The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis Completed NCT00056368 Phase 3
37 Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) Completed NCT00034632 Phase 3
38 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Completed NCT00734539 Phase 3
39 Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients Completed NCT00390780 Phase 3
40 Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Completed NCT00001937 Phase 3
41 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Completed NCT02111629 Phase 3
42 Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis Recruiting NCT00761267 Phase 3
43 A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients Terminated NCT01092832 Phase 3
44 A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis Terminated NCT01176058 Phase 3
45 Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis Completed NCT00659971 Phase 2
46 A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole Completed NCT00001065 Phase 2
47 Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches Completed NCT00835029 Phase 2
48 A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients Completed NCT00002399 Phase 2
49 Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin Completed NCT02525458 Phase 2
50 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2

Search NIH Clinical Center for Oral Candidiasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: candidiasis, oral

Genetic Tests for Oral Candidiasis

Anatomical Context for Oral Candidiasis

MalaCards organs/tissues related to Oral Candidiasis:

39
Skin, Colon, Tongue, T Cells, Testes, Neutrophil, Kidney

Publications for Oral Candidiasis

Articles related to Oral Candidiasis:

(show top 50) (show all 404)
id Title Authors Year
1
Oral candidiasis following steroid therapy for oral lichen planus. ( 26599999 )
2016
2
Adjuvant antifungal therapy using tissue tolerable plasma on oral mucosa and removable dentures in oral candidiasis patients: a randomised double-blinded split-mouth pilot study. ( 26932256 )
2016
3
Elimination of oral candidiasis may increase stimulated whole salivary flow rate. ( 27497081 )
2016
4
Prevention of Oral Candidiasis After Free Flap Surgery: Role of 3% Sodium Bicarbonate Saline in Oral Care. ( 27669373 )
2016
5
Treatment of Oral Candidiasis Using PhotodithazineAr- Mediated Photodynamic Therapy In Vivo. ( 27253525 )
2016
6
Oral Candidiasis among Cancer Patients Attending a Tertiary Care Hospital in Chennai, South India: An Evaluation of Clinicomycological Association and Antifungal Susceptibility Pattern. ( 27403171 )
2016
7
Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. ( 27042008 )
2016
8
Quantification of oral palatine Langerhans cells in HIV/AIDS associated oral Kaposi sarcoma with and without oral candidiasis. ( 27461637 )
2016
9
Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis. ( 27358561 )
2016
10
Oral candidiasis. ( 27343964 )
2016
11
Plasma Levels of IFN-I^, IL-4, IL-6 and IL-17 in HIV-Positive Patients With Oral Candidiasis. ( 27127595 )
2016
12
The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial. ( 27977721 )
2016
13
Molecular analysis of fungal populations in patients with oral candidiasis using next-generation sequencing. ( 27305838 )
2016
14
Topical Antimycotics for Oral Candidiasis in Warfarin Users. ( 27901310 )
2016
15
Development and evaluation of N-naphthyl-N,O-succinyl chitosan micelles containing clotrimazole for oral candidiasis treatment. ( 27050629 )
2016
16
FACTORS RELATED TO ORAL CANDIDIASIS IN ELDERLY USERS AND NON-USERS OF REMOVABLE DENTAL PROSTHESES. ( 27007560 )
2016
17
Elucidating the Role of Hyposalivation and Autoimmunity in Oral Candidiasis. ( 27998016 )
2016
18
Evaluation of effect of topical ozone therapy on salivary Candidal carriage in oral candidiasis. ( 26096109 )
2015
19
Antifungal prescribing pattern and attitude towards the treatment of oral candidiasis among dentists in Jordan. ( 26148537 )
2015
20
Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis. ( 26456226 )
2015
21
Pseudomembranous Type of Oral Candidiasis is Associated with Decreased Salivary Flow Rate and Secretory Immunoglobulin A Levels. ( 25682023 )
2015
22
In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. ( 26416861 )
2015
23
Does scientific evidence for the use of natural products in the treatment of oral candidiasis exist? A systematic review. ( 25883668 )
2015
24
Novel aggregation properties of Candida albicans secreted aspartyl proteinase Sap6 mediates virulence in oral candidiasis. ( 25870228 )
2015
25
Anti-Candida activity of aroma candy and its protective activity against murine oral candidiasis. ( 25855024 )
2015
26
Human immunodeficiency virus induced oral candidiasis. ( 26538978 )
2015
27
Innovation of natural essential oil-loaded Orabase for local treatment of oral candidiasis. ( 26170621 )
2015
28
Clinical implications of oral candidiasis: host tissue damage and disseminated bacterial disease. ( 25422264 )
2015
29
Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis. ( 26719641 )
2015
30
Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. ( 25819801 )
2015
31
Local, systemic, demographic, and health-related factors influencing pathogenic yeast spectrum and antifungal drug administration frequency in oral candidiasis: a retrospective study. ( 26481235 )
2015
32
Fabrication of mucoadhesive chitosan coated polyvinylpyrrolidone/cyclodextrin/clotrimazole sandwich patches for oral candidiasis. ( 26256338 )
2015
33
The changing role of HIV-associated oral candidiasis in the era of HAART. ( 25868223 )
2015
34
Fabrication of a novel scaffold of clotrimazole-microemulsion-containing nanofibers using an electrospinning process for oral candidiasis applications. ( 25543979 )
2015
35
C/EBPI^ Promotes Immunity to Oral Candidiasis through Regulation of I^-Defensins. ( 26317211 )
2015
36
Direct Microscopy: A Useful Tool to Diagnose Oral Candidiasis in Children and Adolescents. ( 26329143 )
2015
37
Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis. ( 26596951 )
2015
38
Age-related alteration of expression and function of TLRs and NK activity in oral candidiasis. ( 25704085 )
2015
39
Development of an antifungal denture adhesive film for oral candidiasis utilizing hot melt extrusion technology. ( 25169007 )
2014
40
Molecular analysis of fungal populations in patients with oral candidiasis using internal transcribed spacer region. ( 24979710 )
2014
41
Defective IL-17- and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene. ( 25344377 )
2014
42
In vitro evaluation of the enzymatic activity profile of non-albicans Candida species isolated from patients with oral candidiasis with or without diabetes. ( 24908598 )
2014
43
Oral candidiasis: An overview. ( 25364186 )
2014
44
Fast-acting clotrimazole composited PVP/HPI^CD nanofibers for oral candidiasis application. ( 24554117 )
2014
45
Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253. ( 24903939 )
2014
46
Immunology of oral candidiasis. ( 25210393 )
2014
47
Virulence of oral Candida isolated from HIV-positive women with oral candidiasis and asymptomatic carriers. ( 25201119 )
2014
48
Oral candidiasis in systemic lupus erythematosus. ( 24598219 )
2014
49
Comparison of the efficacy of a novel sustained release clotrimazole varnish and clotrimazole troches for the treatment of oral candidiasis. ( 24867230 )
2014
50
Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis. ( 24752272 )
2014

Variations for Oral Candidiasis

Expression for Oral Candidiasis

Search GEO for disease gene expression data for Oral Candidiasis.

Pathways for Oral Candidiasis

GO Terms for Oral Candidiasis

Cellular components related to Oral Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 B2M CXCL8 DEFA1 DEFB1 DEFB4A IL1A
2 extracellular region GO:0005576 9.28 B2M CXCL8 DEFA1 DEFB1 DEFB4A HTN3
3 Golgi lumen GO:0005796 9.26 DEFA1 DEFB1 DEFB4A MUC7
4 other organism cell membrane GO:0044218 9.16 LTF MUC7

Biological processes related to Oral Candidiasis according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.8 DEFA1 DEFB1 DEFB4A HTN3 IRF8 LTF
2 chemotaxis GO:0006935 9.78 CXCL8 DEFA1 DEFB1 DEFB4A
3 defense response GO:0006952 9.76 CXCL8 DEFA1 DEFB1 DEFB4A
4 defense response to Gram-positive bacterium GO:0050830 9.71 B2M DEFA1 DEFB1 DEFB4A
5 cellular response to lipopolysaccharide GO:0071222 9.7 B2M CXCL8 IRF8
6 antibacterial humoral response GO:0019731 9.67 B2M DEFA1 DEFB1 LTF
7 antimicrobial humoral response GO:0019730 9.65 DEFA1 DEFB1 DEFB4A HTN3 LTF
8 innate immune response in mucosa GO:0002227 9.61 DEFA1 DEFB1 LTF
9 iron ion homeostasis GO:0055072 9.58 B2M LTF
10 retina homeostasis GO:0001895 9.57 B2M LTF
11 response to bacterium GO:0009617 9.56 DEFB1 IRF8
12 immune response GO:0006955 9.56 B2M CD4 CXCL8 DEFA1 DEFB1 DEFB4A
13 defense response to fungus GO:0050832 9.55 DEFA1 HTN3
14 defense response to Gram-negative bacterium GO:0050829 9.55 B2M CD4 DEFB1 DEFB4A LTF
15 regulation of defense response to virus by virus GO:0050690 9.54 B2M CD4
16 response to molecule of bacterial origin GO:0002237 9.51 B2M CXCL8
17 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.49 CD4 IL1A
18 killing of cells of other organism GO:0031640 9.02 DEFA1 DEFB4A HTN3 LTF MUC7

Molecular functions related to Oral Candidiasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 CCR6 chemokine receptor binding GO:0031731 8.62 DEFB1 DEFB4A

Sources for Oral Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....